Project Grant R01AI195551
Award Date 8/3/26
Completion Date 7/31/31
Dollars Obligated $742K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10016, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded New York University $712,258 on July 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct comparative investigation of two carboxyl-terminal processing proteases (CTPs) in Pseudomonas aeruginosa, a pathogen responsible for acute pneumonia, severe wound infections, and chronic lung colonization in cystic fibrosis patients. The research examines the contrasting roles and mechanisms of PRC and...
- The National Institute of Allergy and Infectious Diseases awarded Northwestern University $431,784 on February 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on Pseudomonas aeruginosa carriage in the gastrointestinal tract. The funded research investigates how hospitalized patients acquire P. aeruginosa colonization in the GI tract, which serves as a major reservoir for subsequent spread to other body sites and infection. The recipient will...
- The National Institute of Allergy and Infectious Diseases awarded $449,578 to the University of California, San Diego on February 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to explore the role of lytic polysaccharide monooxygenases in the virulence and immune evasion mechanisms of Pseudomonas aeruginosa. The research investigates chitin-binding protein D (CBPD), a highly conserved lytic polysaccharide monooxygenase that P. aeruginosa produces to resist host...
- The National Institute of Allergy and Infectious Diseases awarded New York University $254,250 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to test the epigenetic basis and evolutionary generality of bacterial persistence in Staphylococcus aureus. The research examines how bacteria survive antibiotic treatment without genetic changes—a phenomenon distinct from drug resistance and drug tolerance. The project builds on preliminary findings that...
- The National Institute of Allergy and Infectious Diseases awarded Columbia University $560,455 on February 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on the assembly, function, and toxicity of R-bodies in Pseudomonas aeruginosa. R-bodies are bacterial protein structures that kill grazing protists and contribute to host colonization, damage, and virulence in P. aeruginosa, a leading cause of chronic wound and lung infections and one of...
- The National Institute of Allergy and Infectious Diseases awarded the University of Washington $2,306,555 on February 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on molecular determinants and functions of bacterial polysaccharide cellular localization. The research examines PSL and PEL exopolysaccharides in Pseudomonas aeruginosa biofilms, investigating how these polymers localize to cell surfaces and their roles in biofilm formation,...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $571,412 to the University of Maryland, College Park on June 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into the regulation of bacterial physiology and infections through linear diribonucleotides and RNA degradation. The project will characterize how diribonucleases and triribonucleases bind their respective...
- The National Institute of Allergy and Infectious Diseases awarded Eastern Washington University $470,978 on April 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize DAHP synthases in Pseudomonas aeruginosa at the molecular level and support antimicrobial therapeutic development. The project, titled "Unraveling the Biosynthesis of Aromatic Virulence Factors in Pseudomonas aeruginosa," funds basic biochemical research into the enzymatic...
- The National Institute of Allergy and Infectious Diseases awarded the University of Notre Dame DU Lac $709,532 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct systematic research into the cytoplasmic pathway for peptidoglycan recycling in Pseudomonas aeruginosa, an antibiotic-resistant gram-negative bacterial pathogen responsible for recurrent lung infections in cystic fibrosis patients. The work addresses two specific aims. The first...
- The National Institute of Allergy and Infectious Diseases awarded New York University $827,768 on August 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how microbial exposure influences the persistence of long-lived plasma cells in the small intestinal lamina propria. The research will employ imaging and single-cell profiling to define how microbial exposures shape the generation, turnover, and function of long-lived plasma cells by comparing...